186 related articles for article (PubMed ID: 32807838)
1. A vaccine combination of lipid nanoparticles and a cholera toxin adjuvant derivative greatly improves lung protection against influenza virus infection.
Bernasconi V; Norling K; Gribonika I; Ong LC; Burazerovic S; Parveen N; Schön K; Stensson A; Bally M; Larson G; Höök F; Lycke N
Mucosal Immunol; 2021 Mar; 14(2):523-536. PubMed ID: 32807838
[TBL] [Abstract][Full Text] [Related]
2. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.
Eliasson DG; Helgeby A; Schön K; Nygren C; El-Bakkouri K; Fiers W; Saelens X; Lövgren KB; Nyström I; Lycke NY
Vaccine; 2011 May; 29(23):3951-61. PubMed ID: 21481325
[TBL] [Abstract][Full Text] [Related]
3. Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections.
Bernasconi V; Bernocchi B; Ye L; Lê MQ; Omokanye A; Carpentier R; Schön K; Saelens X; Staeheli P; Betbeder D; Lycke N
Front Immunol; 2018; 9():2060. PubMed ID: 30271406
[TBL] [Abstract][Full Text] [Related]
4. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
Eliasson DG; El Bakkouri K; Schön K; Ramne A; Festjens E; Löwenadler B; Fiers W; Saelens X; Lycke N
Vaccine; 2008 Feb; 26(9):1243-52. PubMed ID: 18243429
[TBL] [Abstract][Full Text] [Related]
5. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.
De Filette M; Ramne A; Birkett A; Lycke N; Löwenadler B; Min Jou W; Saelens X; Fiers W
Vaccine; 2006 Jan; 24(5):544-51. PubMed ID: 16169634
[TBL] [Abstract][Full Text] [Related]
6. Intranasal inoculate of influenza virus vaccine against lethal virus challenge.
Fan X; Su Q; Qiu F; Yi Y; Shen L; Jia Z; Liang P; Zou Y; Bi S
Vaccine; 2018 Jul; 36(29):4354-4361. PubMed ID: 29880240
[TBL] [Abstract][Full Text] [Related]
7. Prevention of influenza virus infection and transmission by intranasal administration of a porous maltodextrin nanoparticle-formulated vaccine.
Quan Le M; Ye L; Bernasconi V; Carpentier R; Fasquelle F; Lycke N; Staeheli P; Betbeder D
Int J Pharm; 2020 May; 582():119348. PubMed ID: 32325240
[TBL] [Abstract][Full Text] [Related]
8. Mucosal vaccination of conserved sM2, HA2 and cholera toxin subunit A1 (CTA1) fusion protein with poly gamma-glutamate/chitosan nanoparticles (PC NPs) induces protection against divergent influenza subtypes.
Chowdhury MYE; Kim TH; Uddin MB; Kim JH; Hewawaduge CY; Ferdowshi Z; Sung MH; Kim CJ; Lee JS
Vet Microbiol; 2017 Mar; 201():240-251. PubMed ID: 28284616
[TBL] [Abstract][Full Text] [Related]
9. Intranasal vaccination with a recombinant protein CTA1-DD-RBF protects mice against hRSV infection.
Li H; Ren H; Zhang Y; Cao L; Xu W
Sci Rep; 2021 Sep; 11(1):18641. PubMed ID: 34545126
[TBL] [Abstract][Full Text] [Related]
10. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
11. Lipid nanoparticle composition for adjuvant formulation modulates disease after influenza virus infection in quadrivalent influenza vaccine vaccinated mice.
Jangra S; Lamoot A; Singh G; Laghlali G; Chen Y; Ye T; García-Sastre A; De Geest BG; Schotsaert M
Front Immunol; 2024; 15():1370564. PubMed ID: 38711520
[TBL] [Abstract][Full Text] [Related]
12. The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells.
Helgeby A; Robson NC; Donachie AM; Beackock-Sharp H; Lövgren K; Schön K; Mowat A; Lycke NY
J Immunol; 2006 Mar; 176(6):3697-706. PubMed ID: 16517738
[TBL] [Abstract][Full Text] [Related]
13. Improved design and intranasal delivery of an M2e-based human influenza A vaccine.
De Filette M; Fiers W; Martens W; Birkett A; Ramne A; Löwenadler B; Lycke N; Jou WM; Saelens X
Vaccine; 2006 Nov; 24(44-46):6597-601. PubMed ID: 16814430
[TBL] [Abstract][Full Text] [Related]
14. Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.
Bhide Y; Dong W; Gribonika I; Voshart D; Meijerhof T; de Vries-Idema J; Norley S; Guilfoyle K; Skeldon S; Engelhardt OG; Boon L; Christensen D; Lycke N; Huckriede A
Front Immunol; 2019; 10():646. PubMed ID: 30984200
[TBL] [Abstract][Full Text] [Related]
15. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
[TBL] [Abstract][Full Text] [Related]
16. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.
Akhiani AA; Stensson A; Schön K; Lycke N
Scand J Immunol; 2006 Feb; 63(2):97-105. PubMed ID: 16476008
[TBL] [Abstract][Full Text] [Related]
17. DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination.
Hayashi T; Momota M; Kuroda E; Kusakabe T; Kobari S; Makisaka K; Ohno Y; Suzuki Y; Nakagawa F; Lee MSJ; Coban C; Onodera R; Higashi T; Motoyama K; Ishii KJ; Arima H
Front Immunol; 2018; 9():2619. PubMed ID: 30515151
[TBL] [Abstract][Full Text] [Related]
18. Development of Safe and Non-Self-Immunogenic Mucosal Adjuvant by Recombinant Fusion of Cholera Toxin A1 Subunit with Protein Transduction Domain.
Shim BS; Cheon IS; Lee E; Park SM; Choi Y; Jung DI; Yang E; Choi JA; Chun JY; Kim JO; Yun CH; Czerkinsky C; Song MK
J Immunol Res; 2018; 2018():9830701. PubMed ID: 29707588
[TBL] [Abstract][Full Text] [Related]
19. Intranasal Immunization Using CTA1-DD as a Mucosal Adjuvant for an Inactivated Influenza Vaccine.
Fan XT; Wang YL; Su QD; Qiu F; Yi Y; Jia ZY; Wang DY; Qin K; Zou YN; Bi SL; Shen LP
Biomed Environ Sci; 2019 Jul; 32(7):531-540. PubMed ID: 31331437
[TBL] [Abstract][Full Text] [Related]
20. M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A.
Ibañez LI; Roose K; De Filette M; Schotsaert M; De Sloovere J; Roels S; Pollard C; Schepens B; Grooten J; Fiers W; Saelens X
PLoS One; 2013; 8(3):e59081. PubMed ID: 23527091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]